Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
- February -
March
-
April
-
May
-
June
-
July
-
August
-
September
-
Oktober
-
November
-
December
|
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
- 2020 -
2021
-
2022
-
2023
-
2024
February 2020 - 35 products
L
IP
Ambiful 250 mg/5 ml
2
421.32
473.70
10 %
Injection solution in prefilled syringe: Fulvestrantum 50 mg/ml
Curatis AG
B / SL / SG
FB
G
IP
CI
Co-Amoxicillin Spirig HC 625 mg
(500/125)
10
8.08
25.25
10 %
Coated tablets: 2 Active Agents
Spirig HealthCare AG
A / SL / SG
FB
G
IP
CI
Co-Amoxicillin Spirig HC 625 mg
(500/125)
20
14.31
32.00
10 %
Coated tablets: 2 Active Agents
Spirig HealthCare AG
A / SL / SG
FB
G
IP
CI
Co-Amoxicillin Spirig HC
1000 mg (875/125)
12
13.79
31.45
10 %
Coated tablets: 2 Active Agents
Spirig HealthCare AG
A / SL / SG
FB
G
IP
CI
Co-Amoxicillin Spirig HC
1000 mg (875/125)
20
20.16
38.30
10 %
Coated tablets: 2 Active Agents
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
Daptomycin Accord 350 mg
74.35
97.30
10 %
Pulver zur Herstellung einer Infusions-/Injektionslösung: Daptomycinum 350 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Daptomycin Accord 500 mg
106.20
131.90
10 %
Pulver zur Herstellung einer Infusions-/Injektionslösung: Daptomycinum 500 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Spravato
184.63
217.20
10 %
Nasal spray: Esketaminum 28mg / 0.2ml
Janssen-Cilag AG
A / SL
FB
G
L
IP
Spravato
2
369.26
418.00
10 %
Nasal spray: Esketaminum 28mg / 0.2ml
Janssen-Cilag AG
A / SL
FB
G
L
IP
Spravato
3
553.89
618.80
10 %
Nasal spray: Esketaminum 28mg / 0.2ml
Janssen-Cilag AG
A / SL
FB
G
L
IP
CI
Lorviqua 25 mg
90
3288.55
3592.90
10 %
Coated tablets: Lorlatinibum 25 mg
Pfizer AG
A / SL
FB
G
L
IP
Lorviqua 100 mg
30
4384.73
4785.05
10 %
Coated tablets: Lorlatinibum 100 mg
Pfizer AG
A / SL
FB
G
L
IP
CI
Cerdelga 84 mg
56
25084.71
26044.70
10 %
Capsules: Eliglustatum 84.4 mg
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
CI
Vitamin D3 Spirig HC
30
1.36
2.50
10 %
Soft capsules: Cholecalciferolum 800 UI
Spirig HealthCare AG
●
D / SL
FB
G
L
IP
CI
Vitamin D3 Spirig HC
90
4.08
7.55
10 %
Soft capsules: Cholecalciferolum 800 UI
Spirig HealthCare AG
D / SL
FB
G
L
IP
CI
Nucala 100 mg/mL
1055.33
1164.15
10 %
Injektionslösung im Fertigpen: Mepolizumabum 100mg / 1ml
GlaxoSmithKline AG
B / SL
FB
G
L
IP
CI
Nucala 100 mg/mL
3 x 1
3166.00
3459.65
10 %
Injektionslösung im Fertigpen: Mepolizumabum 100mg / 1ml
GlaxoSmithKline AG
B / SL
FB
G
L
IP
Nucala 100 mg/mL
1055.33
1164.15
10 %
Injektionslösung in der Fertigspritze: Mepolizumabum 100mg / 1ml
GlaxoSmithKline AG
B / SL
FB
G
L
IP
CI
Luxturna 5 x 10e12
319054.57
327657.80
10 %
Konzentrat und Lösungsmittel zur Herstellung einer Injektionslösung: Voretigenum Neparvovecum 5
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Vitamin D3 Spirig HC 2740
I.E./ml
25 ml
3.88
7.15
10 %
ölige Lösung zum Einnehmen: Cholecalciferolum 2740 UI/ml
Spirig HealthCare AG
●
D / SL
FB
G
IP
Xorox 30 mg/g
4.5 g
PR
PR
k.A.
Ophtalmic ointment: Aciclovirum 30 mg
AGEPHA PHARMA s.r.o.,
Bratislava,
Zweigniederlassung Zug
A
FB
G
IP
CI
Helux
5 ml
PR
PR
k.A.
Eye drops: Emedastinum
Future Health Pharma
GmbH
D
FB
G
IP
Ampres intrathecal 10
mg/ml
10 x 5 ml
PR
PR
k.A.
Injection solution: Chloroprocaini Hydrochloridum 10 mg/ml
Sintetica SA
B
FB
G
IP
Ampres intrathecal 10
mg/ml
10 x 5 ml
PR
PR
k.A.
Injection solution: Chloroprocaini Hydrochloridum 10 mg/ml
Sintetica SA
B
FB
G
IP
CI
Xofluza 20 mg
2
PR
PR
k.A.
Coated tablets: Baloxavirum Marboxilum 20 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
CI
Xofluza 20 mg
4
PR
PR
k.A.
Coated tablets: Baloxavirum Marboxilum 20 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
Xofluza 40 mg
PR
PR
k.A.
Coated tablets: Baloxavirum Marboxilum 40 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
Xofluza 40 mg
2
PR
PR
k.A.
Coated tablets: Baloxavirum Marboxilum 40 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
Xofluza 80 mg
PR
PR
k.A.
Coated tablets: Baloxavirum Marboxilum 80 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
CI
Cerdelga 84 mg
14
PR
PR
k.A.
Capsules: Eliglustatum 84.4 mg
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
CI
Cerdelga 84 mg
196
PR
PR
k.A.
Capsules: Eliglustatum 84.4 mg
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
CI
Levocet-Mepha Allergie
10
PR
PR
k.A.
Filmtablette: Levocetirizini Dihydrochloridum 5 mg
Mepha Pharma AG
D
FB
G
IP
CI
Levocet-Mepha Allergie
30
PR
PR
k.A.
Filmtablette: Levocetirizini Dihydrochloridum 5 mg
Mepha Pharma AG
D
FB
G
IP
CI
Levocet-Mepha Allergie
50
PR
PR
k.A.
Filmtablette: Levocetirizini Dihydrochloridum 5 mg
Mepha Pharma AG
D
FB
G
IP
Nucala 100 mg/mL
3 x 1
PR
PR
k.A.
Injektionslösung in der Fertigspritze: Mepolizumabum 100mg / 1ml
GlaxoSmithKline AG
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
